Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Diet and Exercise

X
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of HTD1801 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Diet and Exercise

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berberine ursodeoxycholate (Primary)
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors HighTide Biopharma
  • Most Recent Events

    • 06 Oct 2023 Status changed from active, no longer recruiting to completed, as per results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 Oct 2023 Primary endpoint of Change in hemoglobin A1c (HbA1c) at 12 weeks has been met, as per results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 Oct 2023 Results evaluating the efficacy and safety of HTD1801 , presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top